Patent Term Application for VYLOY (zolbetuximab-clzb), Patent No. 9,212,228 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0863

Patent Term Application for VYLOY (zolbetuximab-clzb), Patent No. 9,212,228

Documents

Comments

Description

OPEN

Comment Period OpensMar 26, 2025

Comment Period ClosesJun 3, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY FR Doc: 2026-06478	Apr 3, 2026	--

CDER

Patent Term Application

Neal, Gerber & Eisenberg LLP

Astellas Pharma Inc.

TRON - Translationale Onkologie

an der Universitatsmedizon der

Johannes Gutenberg-Universitat

Mainz Gemeinnutzige GmbH